On 14 December 2018, orphan designation (EU/3/18/2120) was granted by the European Commission to Takeda Pharma A/S, Denmark, for pevonedistat for the treatment of myelodysplastic syndromes.
|Disease / condition||
Treatment of myelodysplastic syndromes
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.